News
INZY
4.640
+0.87%
0.040
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Dow Jones · 13h ago
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
TipRanks · 13h ago
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Benzinga · 13h ago
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)
TipRanks · 14h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 14h ago
Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities
TipRanks · 14h ago
Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
Inozyme Pharma, Inc. GAAP EPS of -$0.38 beats by $0.02. Cash, cash equivalents, and short-term investments were $166.2 million as of March 31, 2024. The company anticipates to fund cash flow requirements into Q4 2025.
Seeking Alpha · 15h ago
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
Inozyme Pharma reported earnings per share of -38 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -36 cents. Inozyme pharma reported results for first quarter 2024.
Investorplace · 1d ago
Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary
Inozyme Pharma Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 38 cents per share. The mean expectation of six analysts was for a loss of 36 cents. Reported revenue was zero; analysts expected zero. Inozyme Pharmaceutical Inc shares had fallen by 36.3% this quarter.
Reuters · 1d ago
Inozyme Pharma, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 1d ago
Inozyme Pharma Q1 EPS $(0.38) Misses $(0.36) Estimate
Benzinga · 1d ago
*Inozyme Pharma: Runway To Fund Operations Into 4Q 2025 >INZY
Dow Jones · 1d ago
INOZYME PHARMA Q1 NET INCOME USD -23.3 MILLION
Reuters · 1d ago
INOZYME PHARMA INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2024, EXPECTED TO FUND OPERATIONS INTO Q4 OF 2025
Reuters · 1d ago
*Inozyme Pharma 1Q Loss/Shr 38c >INZY
Dow Jones · 1d ago
Press Release: Inozyme Pharma Reports First -2-
forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties. These statements include statements relating to the initiation, timing, and design of planned clinical trials of INZ-701. The Company's actual results could differ materially and adversely from those expressed or implied by such statements.
Dow Jones · 1d ago
Weekly Report: what happened at INZY last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at INZY last week (0422-0426)?
Weekly Report · 04/29 09:04
Weekly Report: what happened at INZY last week (0415-0419)?
Weekly Report · 04/22 09:04
Weekly Report: what happened at INZY last week (0408-0412)?
Weekly Report · 04/15 09:03
More
Webull provides a variety of real-time INZY stock news. You can receive the latest news about Inozyme Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INZY
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.